Erratum: Approach to the Cushing's disease patient with persistent/recurrent hypercortisolism after pituitary surgery (Journal of Clinical Endocrinology and Metabolism (2013) 98, (1307-1318) DOI: 10.1210/jc.2012-3200);Approach to the Cushing's disease patient with persistent/recurrent hypercortisolism after pituitary surgery

Journal of Clinical Endocrinology and Metabolism

Volumn 98, Issue 4, 2013, Pages 1307-1318

  Bertagna, Xavier ^a   Guignat, Laurence ^a  

^a Institut Cochin   (France)

Author keywords

[No Author keywords available]

Indexed keywords

CABERGOLINE; CORTICOTROPIN; DOPAMINE RECEPTOR STIMULATING AGENT; ENZYME INHIBITOR; ETOMIDATE; HYDROCORTISONE; HYPOPHYSIS HORMONE; KETOCONAZOLE; LCI 699; METYRAPONE; MIFEPRISTONE; MITOTANE; OCTREOTIDE; PASIREOTIDE; SOMATOSTATIN DERIVATIVE; UNCLASSIFIED DRUG;

ACTH SECRETING ADENOMA; ADRENAL INSUFFICIENCY; ADRENALECTOMY; ADULT; AMENORRHEA; ANDROGEN DEFICIENCY; ARTICLE; BILATERAL INFERIOR PETROSAL SINUS SAMPLING; CASE REPORT; CAVERNOUS SINUS; CIRCADIAN RHYTHM; CLINICAL FEATURE; CORTICOTROPIN BLOOD LEVEL; CUSHING DISEASE; CUSHING SYNDROME; DRUG BLOOD LEVEL; DRUG CONTRAINDICATION; DRUG DOSE COMPARISON; DRUG DOSE INCREASE; DRUG TOLERABILITY; EDEMA; ENDOCRINE SURGERY; FATIGUE; FEMALE; FOLLOW UP; GAMMA KNIFE RADIOSURGERY; GASTROINTESTINAL SYMPTOM; HIRSUTISM; HORMONE INHIBITION; HORMONE RELEASE; HORMONE SYNTHESIS; HUMAN; HUMAN CELL; HUMAN TISSUE; HYDROCORTISONE BLOOD LEVEL; HYDROCORTISONE URINE LEVEL; HYPERCORTISOLISM; HYPERGLYCEMIA; HYPERTENSION; HYPOKALEMIA; HYPOPHYSECTOMY; HYPOPHYSIS CELL; HYPOPHYSIS FUNCTION; INSULIN RELEASE; MICROADENOMA; MOOD CHANGE; NUCLEAR MAGNETIC RESONANCE IMAGING; PATHOLOGY; PATIENT CARE; PETROSAL SINUS SAMPLING; PRIORITY JOURNAL; PROTEIN TARGETING; PROTON THERAPY; RECURRENT DISEASE; SIDE EFFECT; SINGLE DRUG DOSE; TOXIC HEPATITIS; TRANSSPHENOIDAL SURGERY; TREATMENT OUTCOME; TREATMENT RESPONSE; WEIGHT GAIN;

EID: 84876271934     PISSN: 0021972X     EISSN: 19457197     Source Type: Journal    
DOI: 10.1210/jc.2013-2188     Document Type: Erratum

References (55)

1. Bertagna X, Guignat L, Raux-Demay M-C, Guilhaume B, Girard F. Cushing's disease. In: Melmed S, ed. The Pituitary. 3rd ed. Waltham, MA: Academic Press, Elsevier; 2001:533-618.
2. Newell-Price J, Bertagna X, Grossman AB, Nieman LK. Cushing's syndrome. Lancet. 2006;367:1605-1617.
3. Biller BM, Grossman AB, Stewart PM, et al. Treatment of adrenocorticotropin-dependent Cushing's syndrome: a consensus statement. J Clin Endocrinol Metab. 2008;93:2454-2462.
4. Aghi MK. Management of recurrent and refractory Cushing disease. Nat Clin Pract Endocrinol Metab. 2008;4:560-568.
5. Rees DA, Hanna FW, Davies JS, Mills RG, Vafidis J, Scanlon MF. Long-term follow-up results of transsphenoidal surgery for Cushing's disease in a single centre using strict criteria for remission. Clin Endocrinol (Oxf). 2002;56:541-551.
6. Barker FG 2nd, Klibanski A, Swearingen B. Transsphenoidal surgery for pituitary tumors in the United States, 1996-2000: mortality, morbidity, and the effects of hospital and surgeon volume. J Clin Endocrinol Metab. 2003;88:4709-4719.
7. Dickerman RD, Oldfield EH. Basisofpersistent and recurrent Cushing disease: an analysis of findings at repeated pituitary surgery. J Neurosurg. 2002;97:1343-1349.
8. Clayton RN, Pfeifer M, Atkinson AB, et al. Different patterns of allelic loss (loss of heterozygosity) in recurrent human pituitary tumors provide evidence for multiclonal origins. Clin Cancer Res. 2000;6:3973-3982.
9. Losa M, Mortini P, Dylgjeri S, et al. Desmopressin stimulation test before and after pituitary surgery in patients with Cushing's disease. Clin Endocrinol (Oxf). 2001;55:61-68.
10. Bou Khalil R, Baudry C, Guignat L, et al. Sequential hormonal changes in 21 patients with recurrent Cushing's disease after successful pituitary surgery. Eur J Endocrinol. 2011;165:729-737.
11. Hofmann BM, Hlavac M, Kreutzer J, Grabenbauer G, Fahlbusch R. Surgical treatment of recurrent Cushing's disease. Neurosurgery. 2006;58:1108-1118.
12. Benveniste RJ, King WA, Walsh J, Lee JS, Delman BN, Post KD. Repeated transsphenoidal surgery to treat recurrent or residual pituitary adenoma. J Neurosurg. 2005;102:1004-1012.
13. Ram Z, Nieman LK, Cutler GB Jr, Chrousos GP, Doppman JL, Oldfield EH. Early repeat surgery for persistent Cushing's disease. J Neurosurg. 1994;80:37-45.
14. Locatelli M, Vance ML, Laws ER. Clinical review: the strategy of immediate reoperation for transsphenoidal surgery for Cushing's disease. J Clin Endocrinol Metab. 2005;90:5478-5482.
15. Castinetti F, Nagai M, Morange I, et al. Long-term results of stereotactic radiosurgery in secretory pituitary adenomas. J Clin Endocrinol Metab. 2009;94:3400-3407.
16. Estrada J, Boronat M, Mielgo M, et al. The long-term outcome of pituitary irradiation after unsuccessful transsphenoidal surgery in Cushing's disease. N Engl J Med. 1997;336:172-177.
17. Starke RM, Williams BJ, Vance ML, Sheehan JP. Radiation therapy and stereotactic radiosurgery for the treatment of Cushing's disease: an evidence-based review. Curr Opin Endocrinol Diabetes Obes. 2010;17:356-364.
18. Fernandez A, Brada M, Zabuliene L, Karavitaki N, Wass JA. Radiation-induced hypopituitarism. Endocr Relat Cancer. 2009;16: 733-772.
19. Minniti G, Traish D, Ashley S, Gonsalves A, Brada M. Risk of second brain tumor after conservative surgery and radiotherapy for pituitary adenoma: update after an additional 10 years. J Clin Endocrinol Metab. 2005;90:800-804.
20. Libé R, Groussin L, Bertherat J. Pasireotide in Cushing's disease. N Engl J Med. 2012;366:2134.
21. Pivonello R, De Martino MC, Cappabianca P, et al. The medical treatment of Cushing's disease: effectiveness of chronic treatment with the dopamine agonist cabergoline in patients unsuccessfully treated by surgery. J Clin Endocrinol Metab. 2009;94:223-230.
22. Godbout A, Manavela M, Danilowicz K, Beauregard H, Bruno OD, Lacroix A. Cabergoline monotherapy in the long-term treatment of Cushing's disease. Eur J Endocrinol. 2010;163:709-716.
23. Lila AR, Gopal RA, Acharya SV, et al. Efficacy of cabergoline in uncured (persistent or recurrent) Cushing disease after pituitary surgical treatment with or without radiotherapy. Endocr Pract. 2010; 16:968-976.
24. Hofland LJ, van der Hoek J, Feelders R, et al. The multi-ligand somatostatin analogue SOM230 inhibits ACTH secretion by cultured human corticotroph adenomas via somatostatin receptor type 5. Eur J Endocrinol. 2005;152:645-654.
25. Boscaro M, Ludlam WH, Atkinson B, et al. Treatment of pituitary-dependent Cushing's disease with the multireceptor ligand somatostatin analog pasireotide (SOM230): a multicenter, phase II trial. J Clin Endocrinol Metab. 2009;94:115-122.
26. Colao A, Petersenn S, Newell-Price J, et al; Pasireotide B2305 Study Group. A 12-month phase 3 study of pasireotide in Cushing's disease. N Engl J Med. 2012;366:914-924.
27. Engelhardt D, Weber MM. Therapy of Cushing's syndrome with steroid biosynthesis inhibitors. J Steroid Biochem Mol Biol. 1994; 49:261-267.
28. Jeffcoate WJ, Rees LH, Tomlin S, Jones AE, Edwards CR, Besser GM. Metyrapone in long-term management of Cushing's disease. Br Med J. 1977;2:215-217.
29. Verhelst JA, Trainer PJ, Howlett TA, et al. Short and long-term responses to metyrapone in the medical management of 91 patients with Cushing's syndrome. Clin Endocrinol (Oxf). 1991;35:169-178.
30. Sonino N, Boscaro M, Paoletta A, Mantero F, Ziliotto D. Ketoconazole treatment in Cushing's syndrome: experience in 34 patients. Clin Endocrinol (Oxf). 1991;35:347-352.
31. Castinetti F, Morange I, Jaquet P, Conte-Devolx B, Brue T. Ketoconazole revisited: a preoperative or postoperative treatment in Cushing's disease. Eur J Endocrinol. 2008;158:91-99.
32. Diop SN, Warnet A, Duet M, Firmin C, Mosse A, Lubetzki J. Long-term treatment of Cushing's disease using ketoconazole. Possibility of therapeutic escape [in French]. Presse Med. 1989;18:1325-1328.
33. Schulte HM, Benker G, Reinwein D, Sippell WG, Allolio B. Infusion of low dose etomidate: correction of hypercortisolemia in patients with Cushing's syndrome and dose-response relationship in normal subjects. J Clin Endocrinol Metab. 1990;70:1426-1430.
34. Bertagna X, Pivonello R, Fleseriu M, et al. Patients with Cushing's disease achieve normal urinary cortisol with LCI699, a potent 11β-hydroxylase inhibitor: preliminary results from a multicenter, proof-of-concept study. In: Program of the European Congress of Endocrinology; June 23-26, 2012; Florence, Italy; Oral Communication.
35. Baudry C, Coste J, Bou Khalil R, et al. Efficiency and tolerance of mitotane in Cushing's disease in 76 patients from a single center. Eur J Endocrinol. 2012;16:473-481.
36. Chow JT, Thompson GB, Grant CS, Farley DR, Richards ML, Young WF Jr. Bilateral laparoscopic adrenalectomy for corticotrophin-dependent Cushing's syndrome: a review of the Mayo Clinic experience. Clin Endocrinol (Oxf). 2008;68:513-519.
37. Smith PW, Turza KC, Carter CO, Vance ML, Laws ER, Hanks JB. Bilateral adrenalectomy for refractory Cushing disease: a safe and definitive therapy. J Am Coll Surg. 2009;208:1059-1064.
38. Thompson SK, Hayman AV, Ludlam WH, Deveney CW, Loriaux DL, Sheppard BC. Improved quality of life after bilateral laparoscopic adrenalectomy for Cushing's disease: a 10-year experience. Ann Surg. 2007;245:790-794.
39. Hornyak M, Weiss MH, Nelson DH, Couldwell WT. Nelson syndrome: historical perspectives and current concepts. Neurosurg Focus. 2007;23(3):E12.
40. Assié G, Bahurel H, Coste J, et al. Corticotroph tumor progression after adrenalectomy in Cushing's disease: a reappraisal of Nelson's syndrome. J Clin Endocrinol Metab. 2007;92:172-179.
41. Jornayvaz FR, Assie G, Bienvenu-Perrard M, et al. Pregnancy does not accelerate corticotroph tumor progression in Nelson's syndrome. J Clin Endocrinol Metab. 2011;96:658-662.
42. Chu JW, Matthias DF, Belanoff J, Schatzberg A, Hoffman AR, Feldman D. Successful long-term treatment of refractory Cushing's disease with high-dose mifepristone (RU 486). J Clin Endocrinol Metab. 2001;86:3568-3573.
43. Castinetti F, Fassnacht M, Johanssen S, et al. Merits and pitfalls of mifepristone in Cushing's syndrome. Eur J Endocrinol. 2009;160: 1003-1010.
44. Fleseriu M, Biller BM, Findling JW, Molitch ME, Schteingart DE, Gross C; on behalf of the SEISMIC Study Investigators. Mifepristone, a glucocorticoid receptor antagonist, produces clinical and metabolic benefits in patients with Cushing's syndrome. J Clin Endocrinol Metab. 2012;97:2039-2049.
45. Bertagna X, Bertagna C, Laudat MH, Husson JM, Girard F, Luton JP. Pituitary-adrenal response to the antiglucocorticoid action of RU 486 in Cushing's syndrome. J Clin Endocrinol Metab. 1986;63: 639-643.
46. Schteingart DE, Tsao HS, Taylor CI, McKenzie A, Victoria R, Therrien BA. Sustained remission of Cushing'sdisease with mitotane and pituitary irradiation. Ann Intern Med. 1980;92:613-619.
47. Vilar L, Naves LA, Azevedo MF, et al. Effectiveness of cabergoline in monotherapy and combined with ketoconazole in the management of Cushing's disease. Pituitary. 2010;13:123-129.
48. Kamenicky P, Droumaguet C, Salenave S, et al. Mitotane, metyrapone, and ketoconazole combination therapy as an alternative to rescue adrenalectomy for severe ACTH-dependent Cushing's syndrome. J Clin Endocrinol Metab. 2011;96:2796-2804.
49. Feelders RA, deBruin C, Pereira AM, et al. Pasireotide aloneor with cabergoline and ketoconazole in Cushing's disease. N Engl J Med. 2010;362:1846-1848.
50. Savage MO, Chan LF, Grossman AB, Storr HL. Work-up and management of paediatric Cushing's syndrome. Curr Opin Endocrinol Diabetes Obes. 2008;15:346-351.
51. Stuijver DJ, van Zaane B, Feelders RA, et al. Incidence of venous thromboembolism in patients with Cushing's syndrome: a multicenter cohort study. J Clin Endocrinol Metab. 2011;96:3525-3532.
52. Fukuoka H, Cooper O, Ben-Shlomo A, et al. EGFR as a therapeutic target for human, canine, and mouse ACTH-secreting pituitary adenomas. J Clin Invest. 2011;121:4712-4721.
53. Raverot G, Sturm N, de Fraipont F, et al. Temozolomide treatment in aggressive pituitary tumors and pituitary carcinomas: a French multicenter experience. J Clin Endocrinol Metab. 2010;95:4592-4599.
54. Melmed S. Pathogenesis of pituitary tumors. Nat Rev Endocrinol. 2011;7:257-266.
55. Yacqub-Usman K, Richardson A, Duong CV, Clayton RN, Farrell WE. The pituitary tumour epigenome: aberrations and prospects for targeted therapy. Nat Rev Endocrinol. 2012;8:486-494.